Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964999 | 0.93 | USP2 (0.32) | — | |
| SCHEMBL1982449 | 0.93 | — | — | |
| SCHEMBL1981202 | 0.88 | — | — | |
| SCHEMBL1983634 | 0.86 | — | — | |
| SCHEMBL14801604 | 0.83 | USP2 (0.36) | — | |
| SCHEMBL1986289 | 0.81 | — | — | |
| SCHEMBL1508965 | 0.74 | MEN1 (0.31) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL28589953 | 0.74 | — | — | |
| SCHEMBL23327415 | 0.74 | OPRM1 (0.30) | — | |
| SCHEMBL27036887 | 0.72 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200316065-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-2509980-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | Boehringer Ingelheim International GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071716-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207323-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | MEN1 2447/4885HTT 3837/4885KMT2A 4250/4885 |
| US-20200316065-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | MEN1 2447/4885HTT 3837/4885KMT2A 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.